Issued Pursuant to Section 5, Clauses 3, 6 and 15

Republic of Latvia

Cabinet

Regulation No. 289

Adopted 23 March 2010

Regulations Regarding the Procedures for Conduct of Clinical Trials and Non-interventional Trials of Medicinal Products, Labelling of Investigational Medicinal Products and the Procedures for Assessment of Conformity of Clinical Trial of Medicinal Products with the Requirements of Good Clinical Practice

Issued pursuant to Section 5, Clauses 3, 6 and 15

of the Pharmaceutical Law

I. General Provisions

1. This Regulation prescribes the procedures for the conduct of clinical trials (including multi-centre trials) of medicinal products (except veterinary medicinal products) in accordance with the requirements of good clinical practice and non-interventional trials, as well as the procedures for the labelling of investigational medicinal products and the procedures for assessment of conformity of clinical trials of medicinal products with the requirements of good clinical practice.

2. A trial subject is an individual who participates in a clinical trial, using the investigational medicinal products, or in a control group.

3. An investigational medicinal product is a pharmaceutical form with or without an active substance, which is tested or used as a reference in a clinical trial, including medicinal products already registered, the method of administration, form or packaging, or indications of which differ from the registered or which are used in order to obtain supplementary information regarding the registered type.

4. The investigator is a medical practitioner who in accordance with the regulatory enactments regulating medical treatment has the right to practise medical treatment independently and who has practical experience in the field of medical treatment, which is related to the particular field of a clinical trial.

5. The sponsor is a natural person or a legal person, which takes responsibility for the commencement, management or financing of a clinical trial.

6. The protocol (also amendments made to the protocol) is a document that describes the objective, design, methodology, statistical considerations and the procedures for organisation of a trial, specifies the conditions of inclusion and exclusion of the trial subjects, as well as the procedures for the monitoring of a trial and the publication of the results.

7. A multi-centre clinical trial shall be conducted by several investigators in several sites in accordance with a single trial protocol.Trial sites may be located in one or several Member States of the European Union (hereinafter – Member States), or in Member States and third countries.

8. Trials involving gene therapy and somatic cell therapy medicinal products may only be conducted in specialised medical treatment centres in clinical university hospitals.

9. Information obtained in pre-clinical and clinical trials regarding an investigational medicinal product shall be adequate to support the necessity of the planned clinical trial.

10. The rights, safety and well-being of a trial subject shall prevail over the interests of science and society.

11. The qualification (education, training and experience) of each individual involved in the conduct of a clinical trial shall comply with the tasks to be performed by such person.

12. A clinical trial shall be scientifically sound and guided by ethical principles in all aspects thereof.

13. A clinical trial, including bioavailability and bioequivalence studies, shall be planned, conducted and reported in accordance with the requirements of good clinical practice.

14. Good clinical practice is a set of internationally recognised ethical and scientific requirements of quality, which are complied with in designing, conducting and registering of a clinical trial involving people or in providing reports regarding such trial.

15. Information of a clinical trial shall be recorded, handled and stored in such a way as to ensure the accurate provision, interpretation and verification of the information, concurrently ensuring the protection of confidentiality of the data of the trial subjects.

II. Liability of the Sponsor and the Investigator

16. The investigator and the sponsor, in commencing and conducting a clinical trial, shall comply with this Regulation, as well as the regulatory enactments regulating medical treatment and protection of the data of natural persons.

17. Liability for the medical care of a trial subject and for all the medical decisions related to a clinical trial shall rest with the investigator.The investigator shall also be responsible for the conduct of a clinical trial at a trial site.If a group of individuals conducts a clinical trial, the investigator who is responsible for such a group shall be called the principal investigator.

18. The sponsor shall select the investigator, taking into account his or her qualification and experience.If necessary, the sponsor shall ensure additional training of the investigator.

19. The investigator may participate in trials of phase one if he or she has previous experience in clinical trials of medicinal products.

20. The sponsor may authorise another legal person or natural person for the complete or partial performance of the functions thereof (hereinafter – person authorised by the sponsor).Also in such case the sponsor shall remain fully responsible for the conduct of a clinical trial and the compliance of the data generated by the trial with the requirements of this Regulation.

21. The investigator and the sponsor may be the same person.

22. The sponsor shall insure the civil legal liability thereof and of the investigator, foreseeing the conditions of insurance and compensation.The sponsor shall not be liable for harm that the investigator or other persons involved in the clinical trials have inflicted upon the trial subject deliberately or due to neglect.

23. The sponsor or a legal representative of the sponsor shall be registered in a Member State.If the sponsor or a representative of the sponsor is a natural person, he or she shall have a place of residence declared in the European Union.

24. The sponsor shall ensure the supply of the investigational medicinal product necessary for a clinical trial.The medicinal product shall be manufactured and the quality thereof shall be controlled in accordance with the requirements of good manufacturing practice.

25. The sponsor shall be responsible for the quality of the investigational medicinal product, the supply thereof to the clinical trial site (research centre), the specification of conditions and duration of storage and, where necessary, the dilution liquids and medical devices for the infusion of the medicinal product.All individuals involved in the circulation of the investigational medicinal product shall be informed regarding the referred to conditions.Such persons have the duty to observe the storage conditions of the investigational medicinal product.

26. The investigator shall be responsible for the storage and accounting of the investigational medicinal product in a research centre.

27. The sponsor shall supply the investigational medicinal product, as well as the medical devices for the infusion thereof, if such are necessary, free of charge.

III. The Investigator’s Brochure

28. The investigator’s brochure is a compilation of the clinical and pre-clinical information on the investigational medicinal product regarding the study of the medicinal product, in which human subjects are involved.The information in the investigator’s brochure shall be presented in a concise, simple, objective, balanced and non-promotional form so that a medical practitioner or potential investigator could understand it and make an unbiased assessment of the appropriateness of the proposed clinical trial, taking into account the prospective risks and benefits.These requirements shall also apply to any update of the investigator’s brochure.

29. If an investigational medicinal product is registered in a Member State or state of the European Economic Area, the investigator’s brochure may be substituted for the description of the medicinal product.

30. The sponsor shall evaluate and update the investigator’s brochure at least once a year.

IV. Protection of a Trial Subject

31. A clinical trial may be conducted only in case if:

31.1. it is indicated in the opinion of the Ethics Committee and the permit of the State Agency of Medicines for the commencement of the clinical trial that the anticipated therapeutic benefit for the trial subject and other present or future patients, as well as to the society at large, has been assessed and it justifies the anticipated risk and the clinical trial may be continued if the conformity with this requirement is permanently monitored;

31.2. the trial subject or, when the person is not able to give consent, his or her legal representative has given his or her written voluntary consent to participate in the clinical trial after being informed of the nature, significance, implications and risks of the trial, signing the document of consent of the trial subject drawn up by the sponsor and indicating the date (hereinafter – the informed consent).If the relevant individual is unable to write, oral consent in the presence of at least one witness may be given in exceptional cases;

31.3. the trial subject or, when the person is not able to give the informed consent, his or her legal representative has had the opportunity, in a prior interview with the investigator or another person involved in the conduct of the clinical trial, to understand the objectives, risks and inconveniences of the clinical trial, as well as the conditions, according to which it will be conducted, and the trial subject or, when the person is not able to give the informed consent, his or her legal representative has been informed of the right to withdraw from the participation in the trial at any time;

31.4. the personal data of the trial subject are safeguarded in accordance with the regulatory enactments regarding the protection of the data of natural persons;

31.5. the document of informed consent provides the trial subject with the possibility to discontinue the participation in the clinical trial at any time by informing the sponsor or the investigator regarding revoking of his or her informed consent, and it shall not result in unfavourable impact on the quality of health care provided to the trial subject; and

31.6. the conditions of insurance and compensation are foreseen in the document of informed consent, which cover the civil legal liability of the investigator and the sponsor.

32. In addition to the conditions referred to in Paragraph 31 of this Regulation a clinical trial, in which minors are the trial subjects, may be conducted only in case if the following conditions are complied with:

32.1. the informed consent has been obtained, which has been provided by at least one of the parents or the legal representative.The informed consent shall represent the minor’s presumed will, and it may be revoked at any time without detriment to the minor;

32.2. staff with experience in working with minors has informed the relevant minor in accordance with the capacity of understanding thereof regarding the clinical trial, the risks and benefits thereof.One of the parents or the legal representative shall confirm in writing that the minor has been informed in accordance with the capacity of understanding thereof regarding the nature of the particular clinical trial, the risks and benefits thereof;

32.3. the investigator or the principal investigator has considered the explicit wish of a minor to refuse the participation or to discontinue the participation in the clinical trial at any time, if the relevant minor is capable of forming and justifying his or her opinion and assessing the information referred to in Sub-paragraph 31.3 of this Regulation;

32.4. a minor is not incited or financially induced, except for the compensation of expenditure, which is related to the participation in the clinical trial (including transport expenditure), as well as the compensation for harm caused to health or death caused by the clinical trial;

32.5. direct benefit for the group of patients is expected after the clinical trial, and such trial is essential, in order to validate the data obtained in the clinical trial on persons who are able to give the informed consent or by using other research methods.Such research shall either relate directly to a disease, from which the minor concerned suffers, or be of such a nature that it can only be conducted on minors;

32.6. the scientific instructions of the European Medicines Agency have been followed;

32.7. the clinical trial has been designed so as to minimise pain, discomfort, fear and any other foreseeable risk in relation to the disease and the development stage of the child.Both the risk threshold and the degree of distress have to be specially defined and constantly monitored;

32.8. the Ethics Committee, with paediatric expertise or after taking advice of an expert in clinical, ethical and psychosocial problems in the field of paediatrics, has endorsed the protocol; and

32.9. the interests of the patient prevail over the interests of science and society.

33. To persons who are incapable of giving the informed consent all the requirements referred to in Paragraph 31 of this Regulation, which are applicable to persons who are capable to give such consent, shall apply.If persons who are incapable of giving the informed consent and who have not given such consent or have refused to give the informed consent prior to losing such capabilities, are included in a clinical trial, the trial is allowed if such conditions are complied with in addition to the referred to requirements:

33.1. the informed consent of the legal representative has been obtained.The informed consent shall represent the trial subject’s presumed will, and it may be revoked at any time without detriment to the trial subject;

33.2. the person who is not able to give the informed consent has received information according to his or her capacity of understanding regarding the clinical trial, the risks and benefits thereof;

33.3. the investigator or the principal investigator has considered the explicit wish of a person, if this person is capable of expressing his or her opinion and assessing the information, to refuse the participation in or to discontinue the participation in the clinical trial at any time;

33.4. the person who is not able to give the informed consent is not incited or financially induced, except for the compensation for expenditure, which is related to the participation in the clinical trial (including transport expenditure), as well as the compensation for harm caused to health or death caused by the clinical trial;

33.5. such clinical trial is essential in order to validate the data obtained in the clinical trial on persons who are able to give the informed consent or by using other research methods and relates directly to a life-threatening or debilitating clinical condition, from which the person concerned suffers;

33.6. the clinical trial has been designed so as to minimise pain, discomfort, fear and any other foreseeable risk in relation to the disease and the capability of understanding.Both the risk threshold and the degree of distress have to be specially defined and constantly monitored;

33.7. the Ethics Committee, with expertise in matters related to the relevant disease and the group of patients concerned or after the receipt of advice of an expert in clinical, ethical and psychosocial problems in the field of the relevant disease and the group of patients concerned, has endorsed the protocol;

33.8. the interests of the patient prevail over the interests of science and society; and

33.9. there are grounds to believe that the participation in the clinical trial will be beneficial to the patient outweighing the risks or producing no risk at all.

34. In case of emergency, if it is not possible to receive the informed consent from a trial subject and the trial subject does not have a legal representative or the legal representative is not available, the trial subject shall be involved in a clinical trial only in such case if the protocol includes the procedure of inclusion of a trial subject in case of emergency.

35. In order for a trial subject to receive independent information regarding the relevant clinical trial, the investigator shall provide the trial subject with the contact information of the Ethics Committee (which has provided the opinion regarding the relevant clinical trial) and the State Agency of Medicines.

36. It is prohibited to perform a clinical trial on a pregnant woman and a nursing mother, except in cases when a clinical trial cannot be otherwise conducted, and the risk from conducting the clinical trial is reasonably balanced with the expected benefit for the embryo, foetus or the suckling infant.

37. A trial subject who needs active treatment of a disease shall be included in a control group, in which the trial subject receives a comparator preparation without the active substance, only in the case where the conditions referred to in Paragraphs 31, 32 and 33 of this Regulation are complied with and the protocol includes the scientific and ethical justification of involvement of the trial subjects.

38. In order to ensure the protection of the personal data of a trial subject, the investigator shall assign to each trial subject an identification code, which shall substitute the given name and surname of the trial subject when submitting reports to the sponsor, the State Agency of Medicines and the Ethics Committee.The investigator may decode the given name and surname of a patient only upon the request of such institutions, which in accordance with the Medical Treatment Law have the right to become acquainted with the information regarding the patient.